Role of Chimeric Antigen Receptor T Cell Therapy in Glioblastoma Multiforme.

摘要: Glioblastoma multiforme (GBM) is the most common primary malignant cancer of brain, which extremely aggressive and carries a dreadful prognosis. Current treatment protocol runs around radiotherapy, surgical resection, temozolomide with median overall survival 12–15 months. Due to its heterogeneity mutational load, immunotherapy chimeric antigen receptor (CAR) T cell therapy can be promising option for recurrent glioblastoma. Initial phase 1 studies have shown that this safe without dose-limiting side effects it also has better clinical outcome. Therefore, CAR great future tool in our armamentarium treat advanced GBM. In article, we explained structure, mechanism action, rationale GBM; discussed various antigenic targets outcome initial novel therapy.